- Home
- SNYR vs BIVI Comparison
SNYR vs BIVI Comparison
Compare SNYR & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNYR
- BIVI
- Stock Information
- Founded
- SNYR 2010
- BIVI 2013
- Country
- SNYR United States
- BIVI United States
- Employees
- SNYR N/A
- BIVI N/A
- Industry
- SNYR
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- SNYR
- BIVI Health Care
- Exchange
- SNYR NYSE
- BIVI Nasdaq
- Market Cap
- SNYR 16.6M
- BIVI 15.0M
- IPO Year
- SNYR N/A
- BIVI N/A
- Fundamental
- Price
- SNYR $3.16
- BIVI $7.19
- Analyst Decision
- SNYR Strong Buy
- BIVI
- Analyst Count
- SNYR 1
- BIVI 0
- Target Price
- SNYR $10.00
- BIVI N/A
- AVG Volume (30 Days)
- SNYR 107.9K
- BIVI 42.5K
- Earning Date
- SNYR 08-24-2025
- BIVI 05-12-2025
- Dividend Yield
- SNYR N/A
- BIVI N/A
- EPS Growth
- SNYR N/A
- BIVI N/A
- EPS
- SNYR 0.30
- BIVI N/A
- Revenue
- SNYR $33,592,914.00
- BIVI N/A
- Revenue This Year
- SNYR $37.83
- BIVI N/A
- Revenue Next Year
- SNYR $18.39
- BIVI N/A
- P/E Ratio
- SNYR $10.26
- BIVI N/A
- Revenue Growth
- SNYR N/A
- BIVI N/A
- 52 Week Low
- SNYR $0.36
- BIVI $6.20
- 52 Week High
- SNYR $10.00
- BIVI $75.00
- Technical
- Relative Strength Index (RSI)
- SNYR N/A
- BIVI 31.41
- Support Level
- SNYR N/A
- BIVI $6.78
- Resistance Level
- SNYR N/A
- BIVI $10.30
- Average True Range (ATR)
- SNYR 0.00
- BIVI 0.86
- MACD
- SNYR 0.00
- BIVI -0.29
- Stochastic Oscillator
- SNYR 0.00
- BIVI 19.17
About SNYR SYNERGY CHC CORP
Synergy CHC Corp is a provider of consumer health care, beauty, and lifestyle products. It is engaged in the business of marketing and distributing consumer branded products through various distribution channels in the health and wellness industry. The company's products include FOCUSfactor, Flat Tummy Tea, Hand MD, and Neuragen amongst others. Flat Tummy is a lifestyle and wellness brand that provides a suite of nutritional products to help women achieve their nutrition and weight management goals.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.